(D)-α-bromo-α-(4-tetrahydropyranyl)-acetic acid | 1098638-28-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: (D)-α-bromo-α-(4-tetrahydropyranyl)-acetic acid
• 英文别名: Bromo(tetrahydro-2H-pyran-4-yl)acetic acid；2-Bromo-2-(tetrahydro-2H-pyran-4-yl)acetic acid；2-bromo-2-(oxan-4-yl)acetic acid
• CAS: 1098638-28-8
• 化学式: C₇H₁₁BrO₃
• 分子量: 223.067
• InChiKey: QNJFBCXGERWMLX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Dipeptide derivatives
  申请人：——

  公开号：US20020183260A1

  公开（公告）日：2002-12-05

  Compounds of the formula 1 wherein R, R 1 , COOR 2 , R 3 -R 7 , alk, and X have meaning as defined, such being useful as dual inhibitors of angiotensin converting enzyme and neutral endopeptidase, as well as inhibitors of endothelin converting enzyme.

  式1中的化合物，其中R、R1、COOR2、R3-R7、alk和X的含义如所定义，这些化合物可作为抑制肾素-血管紧张素转化酶和中性内肽酶的双重抑制剂，同时也可作为内皮素转化酶的抑制剂。
• Pyrane derivatives as both ace-and nep-inhibitors
  申请人：——

  公开号：US20040266698A1

  公开（公告）日：2004-12-30

  Compounds of the formula (I), wherein R 1 , R 1 -R 7 and alk have meaning as defined, pharmaceutical compositions thereof, and use thereof for the treatment and/or prevention of cardiovascular disorders responsive to ACE and NEP inhibition and/or ECE inhibition. 1

  化合物的公式(I)，其中R1，R1-R7和alk的含义如定义，其制药组合物，以及用于治疗和/或预防对ACE和NEP抑制和/或ECE抑制有反应的心血管疾病的用途。
• Pyrane derivatives as both ACE- and NEP-inhibitors
  申请人：Fink Anne Cynthia

  公开号：US20060194742A1

  公开（公告）日：2006-08-31

  Compounds of the formula wherein R, R 1 -R 7 and alk have meaning as defined, pharmaceutical compositions thereof, and use thereof for the treatment and/or prevention of cardiovascular disorders responsive to ACE and NEP inhibition and/or ECE inhibition.

  该公式化合物的R、R1-R7和alk具有定义的含义，其药物组合物以及用于治疗和/或预防对ACE和NEP抑制和/或ECE抑制有反应的心血管疾病的用途。
• BICYCLIC HETEROCYCLIC DERIVATIVE
  申请人：Nakahira Hiroyuki

  公开号：US20110190278A1

  公开（公告）日：2011-08-04

  The present invention relates to a compound of the following formula (I) or a pharmaceutically acceptable salt thereof, being useful as a renin inhibitor. [wherein R 1a is halogen, etc.; R 1m is H, etc.; G 1 is —N(R 1b )—, etc.; G 2 is —CO—, etc.; G 3 is —C(R 1c )(R 1d )—, etc.; G 4 is oxygen, etc.; R 1b is optionally substituted C 1-6 alkyl, etc.; R 1c and R 1d are independently the same or different, H, etc.; R 3 is H, optionally substituted C 1-6 alkyl, etc.; R 3a , R 3b , R 3 c and R 3d are independently the same or different, and a group: -A-B (said A is single bond, etc., and said B is H, etc.), etc.; and n is 1, etc.]

  本发明涉及以下式（I）的化合物或其药学上可接受的盐，其可用作肾素抑制剂。[其中，R1a是卤素等；R1m是H等；G1是—N（R1b）—等；G2是—CO—等；G3是—C（R1c）（R1d）—等；G4是氧等；R1b是可选取代的C1-6烷基等；R1c和R1d独立选择为H等；R3是H、可选取代的C1-6烷基等；R3a、R3b、R3c和R3d独立选择为相同或不同的基团：-A-B（其中A是单键等，B是H等）等；n为1等。]
• Essigsäurederivate als Arzneimittel
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP0656348B1

  公开（公告）日：2000-05-03